Rituximab biosimilar - Allergan/Amgen

Drug Profile

Rituximab biosimilar - Allergan/Amgen

Alternative Names: ABP 798; APB-798

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Phase Unknown Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Feb 2017 Investigation in Chronic lymphocytic leukaemia (IV) (Amgen pipeline, February 2014)
  • 14 Oct 2014 Phase-III clinical trials in Non-Hodgkin's lymphoma in Spain (IV)
  • 26 Aug 2014 Phase-III clinical trials in Rheumatoid arthritis in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top